C. Sebban

home / authors / c-sebban

Articles

Site Logo

Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study

Bertrand Coiffier, MD, PhD;C. Fermé;Olivier Hermine, MD, PhD;C. Haioun;E. Baumelou;P. Solal-Celigny;A. Delmer;C. Sebban;N. Mounier;G. Tertian;A. Van Hoof;A. Bosly
March 1st 2002

At the 2000 Annual Meeting of the American Society of Hematology, we presented the benefits of rituximab (Rituxan) combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone), known as R-CHOP, in comparison with CHOP alone for the treatment of elderly patients with diffuse large B-cell lymphoma (DLCL).

Site Logo

Radiotherapy Versis Chemotherapy as ConsolidativeTreatment for Stage IIIB-IV Hodgkin’s Disease in First Complete Remission or Good Partial Response: A Study of 559 Patients (H89 Protocol)

C. Fermé;C. Sebban;F. Berger;P. Lederlin;A. Ferrant;P. Brice;M. Diviné;J. Troncy;L. Voillat;A. Stamattoulas;J. Jaubert;E. Lepage
March 1st 1999

The role of radiotherapy in combination with chemotherapy in advanced-stage Hodgkin’s disease remains controversial.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 51-Year-Old Patient Develops Scaly Plaque on the Right Foot
Published: October 14th 2013 | Updated: July 29th 2025
A 51-Year-Old Patient Develops Scaly Plaque on the Right Foot